{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T21:24:05Z","timestamp":1748121845568},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,4,5]],"date-time":"2002-04-05T00:00:00Z","timestamp":1017964800000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Governments, manufacturers, and other entities are interested in adverse event surveillance of marketed medical products. FDA's Center for Drug Evaluation and Research redesigned the post\u2010marketing adverse reaction surveillance process to use the advantages of new technology. As part of this effort, a \u2018Pharmacovigilance Working Group\u2019 designed a new strategy for the review and analyses of adverse event reports received by FDA. It created requirements which divided signal detection into five tiers: (1) Single \u2018urgent\u2019 reports would be sent to reviewers' workstations nightly for immediate attention. Reviewers would be able to customize definitions of \u2018urgent\u2019 (events that should not wait for aggregate review). (2) Single urgent reports would be placed in a context matrix containing historical counts of similar events to aid in initial interpretation. (3) In this first level of aggregate review, graphical displays would highlight patterns within all the reports, both urgent and non\u2010urgent, and (4) periodic drug\u2010specific tabled\u2010based reports would display the newly received reports across a pre\u2010defined variety of displays. These four tiers would produce passive and criteria\u2010based results which would be presented to safety reviewers' electronic workstations. (5) Active query capabilities (routine, such as age, sex, and year distributions, as well as <jats:italic>ad hoc<\/jats:italic>) would be available for exploring alerted issues. The historical database would be migrated into the new format. All historical and new reaction data would be coded with the new MedDRA (Medical Dictionary for Regulatory Activities) scheme. The strategy was to design a full data capture system which effectively exploits current computing advances and technical performance to automate many aspects of initial adverse event review, supporting more efficient and effective clinical assessment of safety signals. Published in 2002 by John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/pds.684","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:25:36Z","timestamp":1030317936000},"page":"121-125","source":"Crossref","is-referenced-by-count":19,"title":["Automated support for pharmacovigilance: a proposed system"],"prefix":"10.1002","volume":"11","author":[{"given":"Roselie A.","family":"Bright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,5]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"497","volume-title":"Electronic Communication Technologies","author":"Nelson RC","year":"1988"},{"key":"e_1_2_1_3_2","unstructured":"Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications. Title 21 Code of Federal Regulations Sec. 310.305. Also available athttp:\/\/www.access.gpo.gov[28 January2002]."},{"key":"e_1_2_1_4_2","unstructured":"Postmarketing reporting of adverse drug experiences. Title 21 Code of Federal Regulations Sec. 314.80. Also available athttp:\/\/www.access.gpo.gov[28 January2002]."},{"key":"e_1_2_1_5_2","unstructured":"Postmarketing reports. Title 21 Code of Federal Regulations Sec. 314.98. Also available athttp:\/\/www.access.gpo.gov[28 January2002]."},{"key":"e_1_2_1_6_2","unstructured":"Electronic records; electronic signatures. Title 21 Code of Federal Regulations Part 11. Also available athttp:\/\/www. access.gpo.gov[28 January2002]."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550140068042"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/0470842555.ch41"},{"key":"e_1_2_1_10_2","unstructured":"E2A: Definitions and Standards for Expedited Reporting. European Union: issued as CPMP\/ICH\/377\/95. Japan: issued as PAB\/PCD Notification No. 227. United States:Federal Register1995 (March 1);60:11284\u201311287. Internet:http:\/\/www.ifpma.org\/ich5e.html#Safety[28 January2002]."},{"key":"e_1_2_1_11_2","unstructured":"E2B: Data Elements for Transmission of ADR Reports. European Union: issued as CPMP\/ICH\/287\/95. United States:Federal Register1998 (January 15);63:2396\u20132404. Internet:http:\/\/www.ifpma.org\/ich5e.html#Safety[28 January2002]."},{"key":"e_1_2_1_12_2","unstructured":"M2. Electronic Standards for the Transfer of Regulatory Information (ESTRI). Internet:http:\/\/www.fda.gov\/cder\/m2\/m2\u2010main.htm[28 January2002]."},{"key":"e_1_2_1_13_2","unstructured":"E2C. Periodic Safety Update Reports. European Union: issued as CPMP\/ICH\/288\/95. Japan: issued as PAB\/PSD Notification No. 32. USA:Federal Register1997 (May 19);62: 27469\u201327476. Internet:http:\/\/www.ifpma.org\/ich5e.html#Safety[28 January2002]."},{"key":"e_1_2_1_14_2","unstructured":"The Medical Dictionary for Regulatory Activities Terminology. Internet:http:\/\/www.ifpma.org\/ichMedDRA.html[28 January2002]."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2307\/2686093"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:05:26Z","timestamp":1700312726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1002\/pds.684"],"URL":"https:\/\/doi.org\/10.1002\/pds.684","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}